Background: To present the clinical characteristics and treatment outcomes in a relatively large series of patients with periocular metatypical cell carcinoma.
Methods: This is a retrospective study of 35 patients with periocular metatypical cell carcinoma, who were seen between January 2000 and December 2004 in Izmir Ataturk Research and Training Hospital, Turkey. The patients were histologically confirmed metatypical cell carcinoma with radiologic evidence of periocular region. The main outcome measures were patients' demographics, duration of tumour, clinical presentation, tumour site, treatment modalities, recurrence rate and tumour-related exenteration. Statistical comparisons between the nonrecurring group and recurring group were completed using the Cox regression analysis and the log rank test. Significance was determined for all statistical tests as pé 0.05.
Results: The median age of patients at time of diagnosis was 61 years. The most common site for metatypical cell carcinoma was medial canthus and lower eyelid region. The median follow-up for all patients was 18 months. The average length of time until recurrence was 13 months. Five of the 35 patients received adjuvant therapy to the primary tumour site after excision. Signs suggestive of orbital involvement included bone fixation of the mass, limitation of ocular motility and globe displacement. The early lack of diagnostic criteria for metatypical cell carcinoma created considerable debate and confusion regarding its diagnosis. We believe that once this diagnosis is made, the treatment modality should be individualized and chosen with consideration of the extent of orbital involvement, visual function, and the patient's general health.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.bjps.2006.06.007 | DOI Listing |
Case Rep Oncol
November 2024
Faculty of Medicine of Tunis, University of Tunis Manar, Tunis, Tunisia.
Int J Surg Case Rep
December 2024
Department of Surgical Oncology, Salah Azaiez Institute, Tunis, Tunisia.
Introduction: Metatypical basal cell carcinoma is a rare and aggressive subtype of skin cancer. It necessitates a careful and nuanced approach to management. The first-line treatment is a wide surgical excision, which can lead to significant tissue loss.
View Article and Find Full Text PDFAppl Immunohistochem Mol Morphol
October 2024
Department of Dermatology, The First Affiliated Hospital of Chongqing Medical University, Chongqing.
Background: Basaloid skin tumors include subtypes of basal cell carcinoma (BCC) and the basaloid variant of squamous cell carcinoma (SCC). Due to their similarity in pathology and clinical presentation, their diagnosis is not straightforward. The aim of this study was to analyze the immunohistochemical expression of HSP105 in basaloid skin tumors, which include BCC, basosquamous carcinoma (BSC), metatypical basal cell carcinoma (MBCC), basaloid squamous cell carcinoma (BSCC), BCC with squamous differentiation as well as conventional SCC.
View Article and Find Full Text PDFJ Surg Case Rep
October 2024
Department of Surgery, Hackensack Meridian Health, Jersey Shore University Medical Center, Neptune, NJ, 07753, United States.
Environ Sci Pollut Res Int
May 2024
Department of Environmental Science, The University of Burdwan, Golapbag, Purba Bardhaman, Burdwan, West Bengal, India, 713104.
The present study aimed to analyse the integrated histopathological lesions (IHLs) of the gill, liver and intestine of Catla catla exposed to the different doses of UV-B radiation. Gill exhibited the lesions like hypertrophy, hyperplasia, vacuolation, fusion of the gill filaments, rupture in the gill lamellae, epithelial cell lifting and necrosis. The UV-B-exposed liver of Catla showed the lesions like the degeneration of nucleus, the disarrangement of hepatocytes, sinusoidal vacuolation, epitheliod histiocyst, hepatocellular adenoma, exocrine adenoma, cyst formation and diffused epithelial necrosis (DEN).
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!